Gibson also holds options to purchase Recursion Pharmaceuticals stock at prices ranging from $2.48 to $11.40. InvestingPro analysis shows Recursion is quickly burning through cash despite holding more ...
Hosted on MSN
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...
If you've recently come into possession of a new Nintendo Switch 2, first of all, congratulations! You're in for a treat, since the Switch 2 not only has a rapidly growing library of games, but you ...
Hosted on MSN
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback